MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss applicable
to common...
-$8,220,785
Net loss
attributable to...
-$1,173,104
Net loss
-$9,393,889
Gross Product Revenue
$4,878,720
Income tax expense
$264,240
Loss before income
taxes
-$9,129,649
Revenue
$3,944,111
Grosstonet Adjustments
$934,609
Total other income
(expense)
-$110,441
Operating loss
-$9,019,208
Interest income
$45,097
Gross profit
$3,154,903
Cost of revenues
$789,208
Interest expense
$155,538
Total operating
expenses
$12,174,111
Stock-based compensation
general and...
$4,280,227
General and
administrative
$5,720,727
Amortization of in-process
research and development
$573,438
Research and development
$1,599,719
Back
Back
Income Statement
source: myfinsight.com
Citius Pharmaceuticals, Inc. (CTXR)
Citius Pharmaceuticals, Inc. (CTXR)